Which has better earnings & valuation, PEN or LIVN?

Penumbra has higher revenue and earnings than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Penumbra $1.40B 8.92 $177.69M $4.07 78.07 LivaNova $1.39B 2.98 -$242.47M $3.38 22.21

Is PEN or LIVN more profitable?

LivaNova has a net margin of 12.82% compared to Penumbra's net margin of 10.67%. LivaNova's return on equity of 16.35% beat Penumbra's return on equity. Company Net Margins Return on Equity Return on Assets Penumbra 10.67% 10.50% 8.17% LivaNova 12.82% 16.35% 7.76%

Does the media prefer PEN or LIVN?

In the previous week, LivaNova had 1 more articles in the media than Penumbra. MarketBeat recorded 2 mentions for LivaNova and 1 mentions for Penumbra. LivaNova's average media sentiment score of 0.34 beat Penumbra's score of 0.20 indicating that LivaNova is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Penumbra 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral LivaNova 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to BAX or LIVN?

In the previous week, Baxter International had 15 more articles in the media than LivaNova. MarketBeat recorded 17 mentions for Baxter International and 2 mentions for LivaNova. LivaNova's average media sentiment score of 0.34 beat Baxter International's score of -0.13 indicating that LivaNova is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Baxter International 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral LivaNova 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, SNN or LIVN?

Smith & Nephew SNATS has higher revenue and earnings than LivaNova. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Smith & Nephew SNATS $6.16B 1.80 $625M N/A N/A LivaNova $1.39B 2.98 -$242.47M $3.38 22.21

Does the media refer more to SNN or LIVN?

In the previous week, Smith & Nephew SNATS had 1 more articles in the media than LivaNova. MarketBeat recorded 3 mentions for Smith & Nephew SNATS and 2 mentions for LivaNova. LivaNova's average media sentiment score of 0.34 beat Smith & Nephew SNATS's score of -0.01 indicating that LivaNova is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Smith & Nephew SNATS 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral LivaNova 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, LIVN or GMED?

Globus Medical has higher revenue and earnings than LivaNova. Globus Medical is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LivaNova $1.39B 2.98 -$242.47M $3.38 22.21 Globus Medical $2.94B 3.45 $537.87M $3.91 19.34

Is LIVN or GMED more profitable?

Globus Medical has a net margin of 17.02% compared to LivaNova's net margin of 12.82%. LivaNova's return on equity of 16.35% beat Globus Medical's return on equity. Company Net Margins Return on Equity Return on Assets LivaNova 12.82% 16.35% 7.76% Globus Medical 17.02% 14.57% 12.62%

Does the media favor LIVN or GMED?

In the previous week, Globus Medical had 4 more articles in the media than LivaNova. MarketBeat recorded 6 mentions for Globus Medical and 2 mentions for LivaNova. LivaNova's average media sentiment score of 0.34 beat Globus Medical's score of 0.03 indicating that LivaNova is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LivaNova 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Globus Medical 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, PODD or LIVN?

Insulet has higher revenue and earnings than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insulet $2.71B 3.37 $247.10M $5.35 24.61 LivaNova $1.39B 2.98 -$242.47M $3.38 22.21

Is PODD or LIVN more profitable?

LivaNova has a net margin of 12.82% compared to Insulet's net margin of 12.29%. Insulet's return on equity of 29.29% beat LivaNova's return on equity. Company Net Margins Return on Equity Return on Assets Insulet 12.29% 29.29% 13.31% LivaNova 12.82% 16.35% 7.76%

Does the media prefer PODD or LIVN?

In the previous week, Insulet had 5 more articles in the media than LivaNova. MarketBeat recorded 7 mentions for Insulet and 2 mentions for LivaNova. LivaNova's average media sentiment score of 0.34 beat Insulet's score of 0.15 indicating that LivaNova is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insulet 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral LivaNova 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

LivaNova (LIVN) Competitors

$76.33 +1.26 (+1.68%)

As of 01:24 PM Eastern

Compare

LIVN vs. PEN, BAX, SNN, GMED, and PODD

Should you buy LivaNova stock or one of its competitors? LivaNova's main competitors and comparable companies include Penumbra (PEN), Baxter International (BAX), Smith & Nephew SNATS (SNN), Globus Medical (GMED), and Insulet (PODD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does LivaNova compare to Penumbra?

Penumbra (NYSE:PEN) and LivaNova (NASDAQ:LIVN) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

Penumbra currently has a consensus price target of $367.07, indicating a potential upside of 15.53%. LivaNova has a consensus price target of $84.13, indicating a potential upside of 12.06%. Given Penumbra's higher probable upside, equities analysts clearly believe Penumbra is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Penumbra	0 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18
LivaNova	0 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.55

88.9% of Penumbra shares are owned by institutional investors. Comparatively, 97.6% of LivaNova shares are owned by institutional investors. 2.9% of Penumbra shares are owned by company insiders. Comparatively, 0.4% of LivaNova shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, LivaNova had 1 more articles in the media than Penumbra. MarketBeat recorded 2 mentions for LivaNova and 1 mentions for Penumbra. LivaNova's average media sentiment score of 0.34 beat Penumbra's score of 0.20 indicating that LivaNova is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Penumbra	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
LivaNova	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Penumbra has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market. Comparatively, LivaNova has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market.

Penumbra has higher revenue and earnings than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Penumbra	$1.40B	8.92	$177.69M	$4.07	78.07
LivaNova	$1.39B	2.98	-$242.47M	$3.38	22.21

LivaNova has a net margin of 12.82% compared to Penumbra's net margin of 10.67%. LivaNova's return on equity of 16.35% beat Penumbra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Penumbra	10.67%	10.50%	8.17%
LivaNova	12.82%	16.35%	7.76%

Summary

Penumbra and LivaNova tied by winning 8 of the 16 factors compared between the two stocks.

How does LivaNova compare to Baxter International?

Baxter International (NYSE:BAX) and LivaNova (NASDAQ:LIVN) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Baxter International currently has a consensus target price of $22.45, suggesting a potential downside of 4.37%. LivaNova has a consensus target price of $84.13, suggesting a potential upside of 12.06%. Given LivaNova's stronger consensus rating and higher probable upside, analysts clearly believe LivaNova is more favorable than Baxter International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Baxter International	2 Sell rating(s)	9 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
LivaNova	0 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.55

LivaNova has lower revenue, but higher earnings than Baxter International. Baxter International is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Baxter International	$11.24B	1.08	-$957M	-$2.07	N/A
LivaNova	$1.39B	2.98	-$242.47M	$3.38	22.21

In the previous week, Baxter International had 15 more articles in the media than LivaNova. MarketBeat recorded 17 mentions for Baxter International and 2 mentions for LivaNova. LivaNova's average media sentiment score of 0.34 beat Baxter International's score of -0.13 indicating that LivaNova is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Baxter International	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
LivaNova	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

90.2% of Baxter International shares are owned by institutional investors. Comparatively, 97.6% of LivaNova shares are owned by institutional investors. 0.2% of Baxter International shares are owned by insiders. Comparatively, 0.4% of LivaNova shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Baxter International has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market. Comparatively, LivaNova has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market.

LivaNova has a net margin of 12.82% compared to Baxter International's net margin of -9.27%. Baxter International's return on equity of 16.57% beat LivaNova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Baxter International	-9.27%	16.57%	5.24%
LivaNova	12.82%	16.35%	7.76%

Summary

LivaNova beats Baxter International on 13 of the 16 factors compared between the two stocks.

How does LivaNova compare to Smith & Nephew SNATS?

Smith & Nephew SNATS (NYSE:SNN) and LivaNova (NASDAQ:LIVN) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.

25.6% of Smith & Nephew SNATS shares are owned by institutional investors. Comparatively, 97.6% of LivaNova shares are owned by institutional investors. 1.0% of Smith & Nephew SNATS shares are owned by company insiders. Comparatively, 0.4% of LivaNova shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

LivaNova has a net margin of 12.82% compared to Smith & Nephew SNATS's net margin of 0.00%. LivaNova's return on equity of 16.35% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Smith & Nephew SNATS	N/A	N/A	N/A
LivaNova	12.82%	16.35%	7.76%

Smith & Nephew SNATS currently has a consensus price target of $31.91, suggesting a potential upside of 20.63%. LivaNova has a consensus price target of $84.13, suggesting a potential upside of 12.06%. Given Smith & Nephew SNATS's higher possible upside, analysts clearly believe Smith & Nephew SNATS is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Smith & Nephew SNATS	1 Sell rating(s)	10 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
LivaNova	0 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.55

Smith & Nephew SNATS has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market. Comparatively, LivaNova has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market.

Smith & Nephew SNATS has higher revenue and earnings than LivaNova.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smith & Nephew SNATS	$6.16B	1.80	$625M	N/A	N/A
LivaNova	$1.39B	2.98	-$242.47M	$3.38	22.21

In the previous week, Smith & Nephew SNATS had 1 more articles in the media than LivaNova. MarketBeat recorded 3 mentions for Smith & Nephew SNATS and 2 mentions for LivaNova. LivaNova's average media sentiment score of 0.34 beat Smith & Nephew SNATS's score of -0.01 indicating that LivaNova is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Smith & Nephew SNATS	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
LivaNova	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

LivaNova beats Smith & Nephew SNATS on 9 of the 14 factors compared between the two stocks.

How does LivaNova compare to Globus Medical?

LivaNova (NASDAQ:LIVN) and Globus Medical (NYSE:GMED) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

97.6% of LivaNova shares are held by institutional investors. Comparatively, 95.2% of Globus Medical shares are held by institutional investors. 0.4% of LivaNova shares are held by insiders. Comparatively, 18.4% of Globus Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Globus Medical had 4 more articles in the media than LivaNova. MarketBeat recorded 6 mentions for Globus Medical and 2 mentions for LivaNova. LivaNova's average media sentiment score of 0.34 beat Globus Medical's score of 0.03 indicating that LivaNova is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LivaNova	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Globus Medical	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Globus Medical has a net margin of 17.02% compared to LivaNova's net margin of 12.82%. LivaNova's return on equity of 16.35% beat Globus Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	12.82%	16.35%	7.76%
Globus Medical	17.02%	14.57%	12.62%

Globus Medical has higher revenue and earnings than LivaNova. Globus Medical is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.39B	2.98	-$242.47M	$3.38	22.21
Globus Medical	$2.94B	3.45	$537.87M	$3.91	19.34

LivaNova presently has a consensus target price of $84.13, indicating a potential upside of 12.06%. Globus Medical has a consensus target price of $99.46, indicating a potential upside of 31.52%. Given Globus Medical's stronger consensus rating and higher possible upside, analysts clearly believe Globus Medical is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.55
Globus Medical	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	2.88

LivaNova has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market. Comparatively, Globus Medical has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market.

Summary

Globus Medical beats LivaNova on 13 of the 17 factors compared between the two stocks.

How does LivaNova compare to Insulet?

Insulet (NASDAQ:PODD) and LivaNova (NASDAQ:LIVN) are both mid-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Insulet has a beta of 1.11, indicating that its stock price is 11% more volatile than the broader market. Comparatively, LivaNova has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market.

In the previous week, Insulet had 5 more articles in the media than LivaNova. MarketBeat recorded 7 mentions for Insulet and 2 mentions for LivaNova. LivaNova's average media sentiment score of 0.34 beat Insulet's score of 0.15 indicating that LivaNova is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insulet	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
LivaNova	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

97.6% of LivaNova shares are owned by institutional investors. 0.4% of Insulet shares are owned by company insiders. Comparatively, 0.4% of LivaNova shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Insulet presently has a consensus target price of $195.40, suggesting a potential upside of 48.38%. LivaNova has a consensus target price of $84.13, suggesting a potential upside of 12.06%. Given Insulet's higher possible upside, equities research analysts plainly believe Insulet is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insulet	2 Sell rating(s)	11 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.42
LivaNova	0 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.55

LivaNova has a net margin of 12.82% compared to Insulet's net margin of 12.29%. Insulet's return on equity of 29.29% beat LivaNova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insulet	12.29%	29.29%	13.31%
LivaNova	12.82%	16.35%	7.76%

Insulet has higher revenue and earnings than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insulet	$2.71B	3.37	$247.10M	$5.35	24.61
LivaNova	$1.39B	2.98	-$242.47M	$3.38	22.21

Summary

Insulet beats LivaNova on 12 of the 16 factors compared between the two stocks.

Get LivaNova News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LIVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LIVN vs. The Competition

Export

Metric	LivaNova	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.22B	$5.50B	$7.14B	$13.35B
Dividend Yield	N/A	1.79%	2.53%	17.32%
P/E Ratio	22.67	25.61	274.82	26.18
Price / Sales	3.03	68.39	613.38	92.44
Price / Cash	15.52	32.73	27.22	34.70
Price / Book	3.48	5.98	11.30	6.38
Net Income	-$242.47M	$146.97M	$3.50B	$381.35M
7 Day Performance	-0.98%	-0.94%	-1.88%	-0.57%
1 Month Performance	-6.67%	-4.32%	-6.20%	-4.46%
1 Year Performance	43.25%	2.06%	7.50%	1.77%

LivaNova Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LIVN LivaNova	2.6798 of 5 stars	$76.33 +1.7%	$84.13 +10.2%	+40.7%	$4.21B	$1.39B	22.59	3,300
PEN Penumbra	2.5763 of 5 stars	$319.10 +0.1%	$367.07 +15.0%	+24.1%	$12.56B	$1.40B	78.40	4,700
BAX Baxter International	1.1101 of 5 stars	$23.51 +0.6%	$22.45 -4.5%	-1.7%	$12.08B	$11.24B	N/A	37,500	Analyst Revision
SNN Smith & Nephew SNATS	3.2567 of 5 stars	$27.09 +0.7%	$31.91 +17.8%	-27.2%	$11.30B	$6.16B	N/A	16,988	Ex-Dividend
GMED Globus Medical	4.2032 of 5 stars	$74.68 +0.2%	$101.77 +36.3%	+24.9%	$10.01B	$2.94B	19.10	6,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LIVN) was last updated on 10/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LivaNova (LIVN) Competitors

LIVN vs. PEN, BAX, SNN, GMED, and PODD

How does LivaNova compare to Penumbra?

Summary

How does LivaNova compare to Baxter International?

Summary

How does LivaNova compare to Smith & Nephew SNATS?

Summary

How does LivaNova compare to Globus Medical?

Summary

How does LivaNova compare to Insulet?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIVN vs. The Competition

LivaNova Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

LivaNova (LIVN) Competitors

LIVN vs. PEN, BAX, SNN, GMED, and PODD

How does LivaNova compare to Penumbra?

Do analysts recommend PEN or LIVN?

Do insiders & institutionals believe in PEN or LIVN?

Does the media prefer PEN or LIVN?

Which has more volatility & risk, PEN or LIVN?

Which has better earnings & valuation, PEN or LIVN?

Is PEN or LIVN more profitable?

Summary

How does LivaNova compare to Baxter International?

Do analysts recommend BAX or LIVN?

Which has better earnings and valuation, BAX or LIVN?

Does the media refer more to BAX or LIVN?

Do insiders & institutionals have more ownership in BAX or LIVN?

Which has more volatility and risk, BAX or LIVN?

Is BAX or LIVN more profitable?

Summary

How does LivaNova compare to Smith & Nephew SNATS?

Do institutionals and insiders have more ownership in SNN or LIVN?

Is SNN or LIVN more profitable?

Do analysts prefer SNN or LIVN?

Which has more volatility & risk, SNN or LIVN?

Which has higher valuation and earnings, SNN or LIVN?

Does the media refer more to SNN or LIVN?

Summary

How does LivaNova compare to Globus Medical?

Do institutionals & insiders believe in LIVN or GMED?

Does the media favor LIVN or GMED?

Is LIVN or GMED more profitable?

Which has better earnings & valuation, LIVN or GMED?

Do analysts prefer LIVN or GMED?

Which has more risk and volatility, LIVN or GMED?

Summary

How does LivaNova compare to Insulet?

Which has more volatility & risk, PODD or LIVN?

Does the media prefer PODD or LIVN?

Do insiders and institutionals have more ownership in PODD or LIVN?

Do analysts prefer PODD or LIVN?

Is PODD or LIVN more profitable?

Which has better valuation and earnings, PODD or LIVN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIVN vs. The Competition

LivaNova Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools